Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Pfizer Chief, The First Order Of Business Is Research

This article was originally published in The Pink Sheet Daily

Executive Summary

In Read's first presentation to investors, the new chief executive laid out plans to reorganize research as part of a strategy to improve productivity and cut spending by $1.5 billion in 2012.
Advertisement

Related Content

European Notebook: Salmonson Stays At CHMP Helm; Sandoz, AstraZeneca Build New Biologics Facilities
European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
Pfizer Looks To Buy Icagen To Fold Into Neusentis Pain Research Unit
In R&D Shakeup, Pfizer Tries New Outsourcing Model
Despite Recent Setbacks At Pfizer, R&D Chief Is Optimistic About R&D Innovation
Merck Pulls EPS Guidance To Avoid "Indiscriminate Short-Term Cost Cutting"
Back To School: Big Pharmas Test New Models For Tapping Academia
Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era
Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era
Pfizer Plots Major Phase III Push

Topics

Advertisement
UsernamePublicRestriction

Register

PS071805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel